Stratifying Patients for Improved Trial Outcomes – High-Risk vs Low-Risk in the Maverick IPF Survival Trial
- Exploring the premise of stratifying patients by risk level (high vs low)
- Shifting focus from FVC decline to survival as a primary endpoint in clinical trials, and how this could offer more meaningful insights into treatment efficacy for IPF
- Discussing the role of proteomics and biomarkers in identifying high-risk patients and optimizing trial design to better reflect patient populations likely to benefit from treatment.